Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – What’s Next?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down before the market opened on Monday . The stock had previously closed at $7.69, but opened at $6.88. Telix Pharmaceuticals shares last traded at $6.9250, with a volume of 88,006 shares.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Citigroup raised their price target on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.13.

Telix Pharmaceuticals Stock Up 3.7%

The firm has a fifty day moving average of $7.44 and a two-hundred day moving average of $9.16. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Telix Pharmaceuticals (NASDAQ:TLX) last posted its quarterly earnings results on Thursday, February 19th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $414.02 million for the quarter, compared to analyst estimates of $421.50 million. On average, sell-side analysts anticipate that Telix Pharmaceuticals Limited will post 0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TLX. Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth $3,037,000. Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the second quarter valued at about $975,000. Jane Street Group LLC bought a new position in Telix Pharmaceuticals in the second quarter worth about $564,000. IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals during the second quarter valued at about $213,000. Finally, Rhumbline Advisers boosted its holdings in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.